GlobeNewsWire · KRYS · October 15, 2026

Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

Get the app for more

Explore stock news, insights and company research.